Microplasmin, ThromboGenics’ lead drug candidate, is a truncated form of the natural human protein plasmin.
ThromboGenics has recently concluded two Phase III trials of Microplasmin, assessing the patients with vitreomacular adhesion (VMA).
The Phase III trial results showed drug’s potential to transform the treatment of retinal disorders.
MSD Biologics is expected to produce Microplasmin at its US Food and Drug Administration (FDA) and the EMA approved Billingham facility (UK) for commercial production.
ThromboGenics CEO Patrik De Haes said that the signing of this 10-year supply agreement with MSD Biologics is a further important step in preparations to commercialise Microplasmin.
“With this deal in place, we remain on track to file microplasmin with both the FDA and EMA by mid 2011 to gain marketing approval for this exciting potential new treatment option for a broad range of retinal disorders,” Haes said.